Skip to main content
. Author manuscript; available in PMC: 2016 Jun 7.
Published in final edited form as: Gene Ther. 2013 Nov 28;21(2):139–147. doi: 10.1038/gt.2013.66

Table 2.

Study Groups

Groups Type of surgery Implanted cells No. per group Treatment
IA 2-mm defect 2 × 106 LV-BMP-2 3 GCV, day 14–28
IB 2-mm defect 2 × 106 LV-BMP-2 3 PBS, day 14–28
IIA Hind limb muscle pouch 2 × 106 LV-Δtk-T2A-BMP-2 3 GCV, day 0–14
IIB Hind limb muscle pouch 2 × 106 LV-Δtk-T2A-BMP-2 3 PBS, day 0–14
IIIA 2-mm defect 2 × 106 LV-Δtk-T2A-BMP-2 3 GCV, day 0–14
IIIB 2-mm defect 2 × 106 LV-Δtk-T2A-BMP-2 3 PBS, day 0–14
IVA 2-mm defect 5 × 106 LV-Δtk-T2A-Luc 4 GCV, day 14–28
IVB 2-mm defect 5 × 106 LV-Δtk-T2A-Luc 4 PBS, day 14–28
VA 2-mm defect 5 × 106 LV-Δtk-T2A-Luc 5 GCV, day 14–42
VB 2-mm defect 5 × 106 LV-Δtk-T2A-Luc 5 PBS, day 14–42